Literature DB >> 35013593

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.

Addi J Romero-Olmedo1, Axel Ronald Schulz2, Henrik E Mei2, Christian Keller3, Michael Lohoff4, Svenja Hochstätter3, Dennis Das Gupta1, Iiris Virta2, Heike Hirseland2, Daniel Staudenraus1, Bärbel Camara1, Carina Münch3, Véronique Hefter3, Siddhesh Sapre3, Verena Krähling3, Helena Müller-Kräuter3, Marek Widera5.   

Abstract

Here we compared SARS-CoV-2-specific antibody and T-cell responses between older adults (>80 years old, n = 51) and a younger control group (20-53 years old, n = 46) after receiving two doses of BNT162b2. We found that responses in older adults were generally lower, and we identified 10% low-/non-responders. After receiving a third vaccination with BNT162b2, 4 out of 5 low-/non-responders showed antibody and T-cell responses similar to those of responders after two vaccinations.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35013593     DOI： 10.1038/s41564-021-01046-z

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN： 2058-5276            Impact factor:   17.745


  1 in total

1.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245
  1 in total
  10 in total

1.  Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.

Authors:  Michal Podrazil; Pavla Taborska; Dmitry Stakheev; Michal Rataj; Jan Lastovicka; Alena Vlachova; Petr Pohunek; Jirina Bartunkova; Daniel Smrz
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

2.  Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old.

Authors:  Rossella Tomaiuolo; Chiara Di Resta; Marco Viganò; Giuseppe Banfi; Cristina Russo; Giulia Linardos; Stefania Ranno; Carlo Federico Perno; Francesco Giuffrida
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

3.  Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2.

Authors:  Rieke Reiter; Pia Von Blanckenburg; Reinier Mutters; Julia Thiemer; Reinhard Geßner; Ulf Seifart
Journal:  Vaccines (Basel)       Date:  2022-05-16

4.  Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years.

Authors:  Addi J Romero-Olmedo; Axel Ronald Schulz; Svenja Hochstätter; Dennis Das Gupta; Heike Hirseland; Daniel Staudenraus; Bärbel Camara; Kirsten Volland; Véronique Hefter; Siddhesh Sapre; Verena Krähling; Helena Müller-Kräuter; Ho-Ryun Chung; Henrik E Mei; Christian Keller; Michael Lohoff
Journal:  Lancet Infect Dis       Date:  2022-04-06       Impact factor: 71.421

Review 5.  In vivo fate and intracellular trafficking of vaccine delivery systems.

Authors:  Jaiwoo Lee; Dongyoon Kim; Junho Byun; Yina Wu; Jinwon Park; Yu-Kyoung Oh
Journal:  Adv Drug Deliv Rev       Date:  2022-05-10       Impact factor: 17.873

6.  TMPRSS2, a novel host-directed drug target against SARS-CoV-2.

Authors:  Christian Keller; Eva Böttcher-Friebertshäuser; Michael Lohoff
Journal:  Signal Transduct Target Ther       Date:  2022-07-23

7.  Will People Accept a Third Booster Dose of the COVID-19 Vaccine? A Cross-Sectional Study in China.

Authors:  Yufang Sun; Hang Dai; Ping Wang; Xiaodong Zhang; Dongliang Cui; Yongping Huang; Jimei Zhang; Tao Xiang
Journal:  Front Public Health       Date:  2022-07-12

8.  Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong.

Authors:  Lin-Lei Chen; Syed Muhammad Umer Abdullah; Wan-Mui Chan; Brian Pui-Chun Chan; Jonathan Daniel Ip; Allen Wing-Ho Chu; Lu Lu; Xiaojuan Zhang; Yan Zhao; Vivien Wai-Man Chuang; Albert Ka-Wing Au; Vincent Chi-Chung Cheng; Siddharth Sridhar; Kwok-Yung Yuen; Ivan Fan-Ngai Hung; Kwok-Hung Chan; Kelvin Kai-Wang To
Journal:  Nat Commun       Date:  2022-06-24       Impact factor: 17.694

9.  Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases.

Authors:  Keren Masha Rabinowitz; Michal Navon; Hadar Edelman-Klapper; Eran Zittan; Ariella Bar-Gil Shitrit; Idan Goren; Irit Avni-Biron; Jacob E Ollech; Lev Lichtenstein; Hagar Banai-Eran; Henit Yanai; Yifat Snir; Maor H Pauker; Adi Friedenberg; Adva Levy-Barda; Arie Segal; Yelena Broitman; Eran Maoz; Baruch Ovadia; Maya Aharoni Golan; Eyal Shachar; Shomron Ben-Horin; Nitsan Maharshak; Michal Mor; Haim Ben Zvi; Rami Eliakim; Revital Barkan; Tali Sharar-Fischler; Sophy Goren; Noy Krugliak; Edward Pichinuk; Michael Mor; Michal Werbner; Joel Alter; Hanan Abu-Taha; Kawsar Kaboub; Moshe Dessau; Meital Gal-Tanamy; Dani Cohen; Natalia T Freund; Iris Dotan
Journal:  Vaccines (Basel)       Date:  2022-07-26

10.  A ubiquitous bone marrow reservoir of preexisting SARS-CoV-2-reactive memory CD4+ T lymphocytes in unexposed individuals.

Authors:  Jinchan Li; Simon Reinke; Yu Shen; Lena Schollmeyer; Yuk-Chien Liu; Zixu Wang; Sebastian Hardt; Christian Hipfl; Ute Hoffmann; Stefan Frischbutter; Hyun-Dong Chang; Tobias Alexander; Carsten Perka; Helena Radbruch; Zhihai Qin; Andreas Radbruch; Jun Dong
Journal:  Front Immunol       Date:  2022-10-04       Impact factor: 8.786
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.